Evidence map›Paper›PMID 39545363›Full record

ArticleFEMS yeast research2024

A multidimensional assessment of in-host fitness costs of drug resistance in the opportunistic fungal pathogen Candida glabrata.

Amir Arastehfar, Farnaz Daneshnia, Hrant Hovhannisyan, Nathaly Cabrera, Macit Ilkit, Jigar V Desai, Toni Gabaldón, Erika Shor, David S Perlin

Abstract read
In one paragraph

Article in FEMS yeast research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. bioRxiv : the preprint server for biology · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amir ArastehfarCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.
Farnaz DaneshniaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.
Hrant HovhannisyanLife Sciences Programme, Supercomputing Center (BSC-CNS), 08034 Barcelona, Spain.
Nathaly CabreraCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.
Macit IlkitDivision of Mycology, Department of Microbiology, Faculty of Medicine, University of Çukurova, 01330 Adana, Turkey.ORCID 0000-0002-1174-4182
Jigar V DesaiCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.
Toni GabaldónLife Sciences Programme, Supercomputing Center (BSC-CNS), 08034 Barcelona, Spain.ORCID 0000-0003-0019-1735
Erika ShorCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.ORCID 0000-0003-3655-0963
David S PerlinCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, United States.

Funding

Critical Factors Influencing Echinocandin Resistance in CandidaglabrataR01AI109025 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI PERLIN, DAVID S · 2014 to 2025
$9.8M
NIAID NIH HHS R01 AI109025NIH HHS R01 R01AI109025
6 · The paper itself

Abstract

Drug-resistant microbes typically carry mutations in genes involved in critical cellular functions and may therefore be less fit under drug-free conditions than susceptible strains. Candida glabrata is a prevalent opportunistic yeast pathogen with a high rate of fluconazole resistance (FLZR), echinocandin resistance (ECR), and multidrug resistance (MDR) relative to other Candida. However, the fitness of C. glabrata MDR isolates, particularly in the host, is poorly characterized, and studies of FLZR isolate fitness have produced contradictory findings. Two important host niches for C. glabrata are macrophages, in which it survives and proliferates, and the gut. Herein, we used a collection of clinical and lab-derived C. glabrata isolates to show that FLZR C. glabrata isolates are less fit inside macrophages than susceptible isolates and that this fitness cost is reversed by acquiring ECR mutations. Interestingly, dual-RNAseq revealed that macrophages infected with drug-resistant isolates mount an inflammatory response whereas intracellular drug-resistant cells downregulate processes required for in-host adaptation. Furthermore, drug-resistant isolates were outcompeted by their susceptible counterparts during gut colonization and in infected kidneys, while showing comparable fitness in the spleen. Collectively, our study shows that macrophage-rich organs, such as the spleen, favor the retention of MDR isolates of C. glabrata.

Indexed as

Antifungal AgentsCandida glabrataCandidiasisDrug Resistance, FungalMacrophagesAnimalsDrug Resistance, Multiple, FungalEchinocandinsFluconazoleGenetic FitnessHumansMiceMicrobial Sensitivity TestsMutationAntifungal AgentsEchinocandinsFluconazoleCandida glabrataechinocandin resistantfitness costfluconazole resistantgut colonizationintracellular replicationmultidrug resistantsystemic infection

Identifiers

PMID39545363
PMCPMC11631428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.